November 09, 2023
橙子视频app Rx Takes Additional Steps to Lower the Cost of Insulin
Beginning Jan. 1, 2024, 橙子视频app Rx will place eight preferred insulin products on tier one of standard commercial formularies, limiting out-of-pocket spend to $35 or less.
橙子视频app Rx, a pharmacy services company, today announced additional actions to make insulin more affordable, moving several rapid-, short- and long-acting insulins to tier one, which offers the lowest cash price consumers pay. This is the latest effort by 橙子视频app Rx to ensure consumers have access to affordable medications and are protected from the high prices set by drug manufacturers.
In all, 橙子视频app Rx will shift eight products, including all short- and rapid-acting insulins, to tier one, or “preferred” status on standard formularies. Three manufacturers will have products added to tier one, including Eli Lilly, Novo Nordisk and Sanofi.
In 2022, the company supported UnitedHealthcare in its work to eliminate copays for consumers in group fully insured plans for insulin and other critical drugs used to treat emergencies such as severe allergic reactions, hypoglycemia, opioid overdoses and acute asthma attacks. In total, 170 unique medications are part of the 橙子视频app Rx Critical Drug Affordability program that includes a recommended cost share of $35 or less for consumers.
Today more than 70% of people who use 橙子视频app Rx already pay less than $35 per month on insulin. Effective Jan. 1, 2024, thanks to the latest actions by 橙子视频app Rx, 98% of all 橙子视频app Rx consumers will have access to insulin for $35 or less per month.
“I’ve seen firsthand how high prices for insulin and other necessary medications can cause patients to limit or skip doses,” said Dr. Patrick Conway, chief executive officer of 橙子视频app Rx. “Medicine that people can’t afford is useless, and by taking this important next step to change our formulary, we will lower costs and improve access for more people who need this life-saving medication. Our goal is to make all essential medicines affordable.”??
Drug manufacturers have the sole discretion over setting and raising prescription drug prices. Pharmacy benefit managers, including 橙子视频app Rx, serve as the counterweight to the manufacturers and are the only player in the prescription drug supply chain actively working to lower drug costs. This formulary decision builds on a series of 橙子视频app Rx actions to help protect consumers from high and rising drug prices and provide them with more choices.
Last January, 橙子视频app Rx launched Price Edge, a consumer solution that seamlessly compares available direct-to-consumer pricing for traditional generic drugs with insurance pricing to ensure people who use 橙子视频app Rx always get the lowest available prescription drug price. 橙子视频app Rx will continue to roll out products, services and policy initiatives to make medications more affordable and provide consumers more information to make decisions on their health care. Learn more about 橙子视频app Rx’s consumer affordability actions?.?
About 橙子视频app Rx
橙子视频app Rx, UnitedHealth Group’s (NYSE: UNH) pharmacy care business, is a pharmacy care business providing people with more affordable access to prescription medications and therapies. This strategy has proven to lower costs for clients and members, improve quality of care and enhance the member experience. Powered by deep clinical expertise and integrated data and analytics, our full-spectrum pharmacy services simplify how consumers, clients and partners navigate the pharmacy space to deliver improved experiences, better health outcomes and a lower total cost of care. 橙子视频app Rx is part of 橙子视频app, a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. For more information, visit?optum.com/optumrx?or follow?橙子视频app Rx on .
?
橙子视频app Media Contact:
newsroom@optum.com